Literature DB >> 7556302

Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma.

J Lin1, W T Leung, S K Ho, K C Ho, S M Kumta, C Metreweli, P J Johnson.   

Abstract

Thallium-201 has been shown to be useful in predicting tumour viability in patients undergoing neoadjuvant chemotherapy for osteogenic sarcoma. Early studies relied upon qualitative assessment of analog images to obtain predictive results. Recently, the lesion to normal tissue uptake ratio of 201Tl has been used in evaluating bone and soft tissue sarcomas. This study attempts to quantitate changes in tumour to normal tissue ratio following chemotherapy. Eight consecutive patients with classical osteosarcoma received standard preoperative chemotherapy with a combination of cisplatin, adriamycin and high-dose methotrexate. 201Tl gamma scintigraphic images were obtained both before and after chemotherapy. The average counts taken over the tumour divided by that from the contralateral normal tissue area yielded a tumour-to-normal tissue (T/N) ratio. The percentage change in the T/N ratio before and after preoperative chemotherapy was correlated with the percentage of tumour necrosis from pathological section. The median post-chemotherapy T/N ratio was 1.85 (range 0.5-7.7). The median percentage change in T/N ratio after chemotherapy was -58% (range +26% to -83%). The median percentage of necrosis from pathological section was 80% (range 0%-95%). There was a good correlation between the percentage of tumour necrosis and the percentage change in T/N ratio (rank correlation coefficient r = 0.84, P = 0.0085). Quantitative assessment of changes in 201Tl uptake by osteosarcoma correlates well with tumour necrosis after preoperative chemotherapy. This method may be used to predict response to chemotherapy at an earlier stage, enabling the clinician to consider alternative chemotherapeutic regimens or salvage surgery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556302     DOI: 10.1007/bf00817281

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

1.  Serial thallium-201 scintigraphy in osteosarcoma. Correlation with tumor necrosis after preoperative chemotherapy.

Authors:  G Rosen; G J Loren; E W Brien; L Ramana; A Waxman; S Lowenbraun; J J Eckardt; F Eilber; L Menendez; J M Mirra
Journal:  Clin Orthop Relat Res       Date:  1993-08       Impact factor: 4.176

2.  The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas.

Authors:  C I Caluser; H M Abdel-Dayem; H A Macapinlac; A Scott; J H Healey; A Huvos; H Kalaigian; S D Yeh; S M Larson
Journal:  Eur J Nucl Med       Date:  1994-11

3.  The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors.

Authors:  C Caluser; H Macapinlac; J Healey; F Ghavimi; P Meyers; N Wollner; J Kalaigian; L Kostakoglu; H M Abdel-Dayem; S D Yeh
Journal:  Clin Nucl Med       Date:  1992-07       Impact factor: 7.794

4.  Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response.

Authors:  L Ramanna; A Waxman; G Binney; S Waxman; J Mirra; G Rosen
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

5.  Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy.

Authors:  G Rosen; R C Marcove; A G Huvos; B I Caparros; J M Lane; A Nirenberg; A Cacavio; S Groshen
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

6.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

7.  Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy.

Authors:  L R Menendez; B M Fideler; J Mirra
Journal:  J Bone Joint Surg Am       Date:  1993-04       Impact factor: 5.284

8.  Mechanism of 201Tl uptake in tumours.

Authors:  A M Sehweil; J H McKillop; R Milroy; R Wilson; H M Abdel-Dayem; Y T Omar
Journal:  Eur J Nucl Med       Date:  1989
  8 in total
  6 in total

Review 1.  Clinical applications of molecular imaging in sarcoma evaluation.

Authors:  Rodney J Hicks; Guy C Toner; Peter F M Choong
Journal:  Cancer Imaging       Date:  2005-06-21       Impact factor: 3.909

Review 2.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

3.  Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma.

Authors:  Kevin B Jones; Peter C Ferguson; Brian Lam; David J Biau; Sevan Hopyan; Benjamin Deheshi; Anthony M Griffin; Lawrence M White; Jay S Wunder
Journal:  J Bone Joint Surg Am       Date:  2012-08-01       Impact factor: 5.284

4.  The role of thallium-201 and pentavalent dimercaptosuccinic acid for staging cartilaginous tumours.

Authors:  Peter Fm Choong; Toshiyuki Kunisada; John Slavin; Stephen Schlicht; Rodney Hicks
Journal:  Int Semin Surg Oncol       Date:  2004-11-08

Review 5.  Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications.

Authors:  Fan-Lin Kong; Richard J Ford; David J Yang
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411

6.  Prognostic value of radiological response to chemotherapy in patients with osteosarcoma.

Authors:  Shinji Miwa; Akihiko Takeuchi; Toshiharu Shirai; Junichi Taki; Norio Yamamoto; Hideji Nishida; Katsuhiro Hayashi; Yoshikazu Tanzawa; Hiroaki Kimura; Kentaro Igarashi; Akishi Ooi; Hiroyuki Tsuchiya
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.